Literature DB >> 23136105

[Immunoadsorption in thrombangiitis obliterans: a promising therapeutic option: results of a consecutive patient cohort treated in clinical routine care].

P F Klein-Weigel1, C Köning, A Härtwig, K Krüger, B Gutsche-Petrak, S Dreusicke, U Thieme, K Enke-Melzer, B Urbach, J Kron.   

Abstract

BACKGROUND: Thrombangiitis obliterans or Buerger's disease is a segmental inflammatory disease affecting small and medium-sized veins and arteries, which most often affects young smokers leading to thrombophlebitis and acral ischaemic syndromes, inducing high amputation rates. Based on positive results of a former pilot study we report on our results of immunoadsorption (IA) in clinical routine care, where IA was offered as a treatment option. PATIENTS AND METHODS: The uncontrolled course of 12 consecutive TAO-patients treated by IA on a series of 5 consecutive days was observed. Follow-up period was 14.1 (ranging from 1-26) months.
RESULTS: Eight patients were treated with one, four patients completed 2 IA-series. In 9 patients an early onset and lasting clinical improvement and an improvement of ischaemia was noted. The intake of pain-relievers (especially opioids) sank drastically. Eight patients returned to work. Retrospectively, in two out of three treatment failures the correct diagnosis of TAO was questionable.
CONCLUSION: IA seems to be a promising treatment option for patients suffering from TAO which should be further evaluated in controlled clinical trials. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2012        PMID: 23136105     DOI: 10.1055/s-0032-1315141

Source DB:  PubMed          Journal:  Zentralbl Chir        ISSN: 0044-409X            Impact factor:   0.942


  1 in total

Review 1.  Buerger's disease: providing integrated care.

Authors:  Peter Klein-Weigel; Theresa Sophie Volz; Leonora Zange; Jutta Richter
Journal:  J Multidiscip Healthc       Date:  2016-10-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.